AVROXA

Technologiepark-Zwijnaarde 82

9052 Gent

BE

AVROXA

Foundation date

10/01/2018

Sector

#Medical Technology

Subsector

AVROXA is a research and manufacturing company committed to the development of innovative solutions based on our versatile proprietary polymer platform technology of poly(2-oxazoline)s (abbreviated as POZ, PAOx,POX). We develop a vast range of high-quality, well-defined, ultra-pure poly(2-oxazoline)s under the brandname ULTROXA(R) for applications in therapeutics, drug delivery, biomaterials and diagnostics.

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    1 day ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022